4.6 Review

Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer

Journal

CANCERS
Volume 13, Issue 15, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13153920

Keywords

BRCA1; BRCA2; clinical trial; pancreatic cancer; p53; translational research; tumor suppressor gene

Categories

Funding

  1. Ministry of Science and Technology [MOST 109-2314-B-037-119, MOST 109-2320-B-037-033]
  2. National Health Research Institutes [NHRI-EX109-10720SI]
  3. Kaohsiung Medical University Hospital [SA10803C]
  4. Kaohsiung Medical University Research Center [KMU-TC109A02, KMU-TC109A02-0, KMU-TC109A02-3]

Ask authors/readers for more resources

Tumor suppressor genes play critical roles in cancer development, with loss of function or mutations contributing to abnormal cell growth, differentiation, and cancer progression. Understanding the roles of tumor suppressor gene products and identifying novel therapeutic targets are crucial for combating aggressive cancers like pancreatic cancer.
Simple Summary Tumor suppressor genes are critical in the control of many biological functions. They can be classified based on their roles in proliferation, cell-cycle progression, DNA repair/damage, and crucial signaling functions, including apoptosis, autophagy, and necrosis. The absence of functional tumor suppressor genes entails a higher risk of dysfunction of cell growth, differentiation, cell death, and cancer development. Loss of function or mutations of such genes has been identified in many types of cancer, such as breast, bladder, colorectal, head and neck, lung, ovarian, uterine, and pancreatic cancers. Familial cancer syndromes, such as Li-Fraumeni syndrome, are associated with loss of TP53 function. Extensive studies have been carried out to clarify the roles of the products of these genes, as well as their mechanistic link to cancers, to identify novel targets for specific cancer types. Here, we introduce the roles of tumor suppressor gene products in pancreatic cancer development and its therapeutics for tumorigenesis prevention. The high mortality of pancreatic cancer is attributed to the insidious progression of this disease, which results in a delayed diagnosis and advanced disease stage at diagnosis. More than 35% of patients with pancreatic cancer are in stage III, whereas 50% are in stage IV at diagnosis. Thus, understanding the aggressive features of pancreatic cancer will contribute to the resolution of problems, such as its early recurrence, metastasis, and resistance to chemotherapy and radiotherapy. Therefore, new therapeutic strategies targeting tumor suppressor gene products may help prevent the progression of pancreatic cancer. In this review, we discuss several recent clinical trials of pancreatic cancer and recent studies reporting safe and effective treatment modalities for patients with advanced pancreatic cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available